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Abstract
Genome-wide association studies (GWAS) are routinely being used to examine the genetic contribution to complex human
traits, such as high-density lipoprotein cholesterol (HDL-C). Although HDL-C levels are highly heritable (h
2,0.7), the genetic
determinants identified through GWAS contribute to a small fraction of the variance in this trait. Reasons for this
discrepancy may include rare variants, structural variants, gene-environment (GxE) interactions, and gene-gene (GxG)
interactions. Clinical practice-based biobanks now allow investigators to address these challenges by conducting GWAS in
the context of comprehensive electronic medical records (EMRs). Here we apply an EMR-based phenotyping approach,
within the context of routine care, to replicate several known associations between HDL-C and previously characterized
genetic variants: CETP (rs3764261, p=1.22e-25), LIPC (rs11855284, p=3.92e-14), LPL (rs12678919, p=1.99e-7), and the
APOA1/C3/A4/A5 locus (rs964184, p=1.06e-5), all adjusted for age, gender, body mass index (BMI), and smoking status. By
using a novel approach which censors data based on relevant co-morbidities and lipid modifying medications to construct a
more rigorous HDL-C phenotype, we identified an association between HDL-C and TRIB1, a gene which previously resisted
identification in studies with larger sample sizes. Through the application of additional analytical strategies incorporating
biological knowledge, we further identified 11 significant GxG interaction models in our discovery cohort, 8 of which show
evidence of replication in a second biobank cohort. The strongest predictive model included a pairwise interaction between
LPL (which modulates the incorporation of triglyceride into HDL) and ABCA1 (which modulates the incorporation of free
cholesterol into HDL). These results demonstrate that gene-gene interactions modulate complex human traits, including
HDL cholesterol.
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Introduction
To date, nearly 600 genome-wide association studies (GWAS)
have been completed, investigating 150 distinct complex human
traits [1,2]. Circulating levels of high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyc-
erides (TG) are quantitative traits commonly measured in clinical
practice and strongly associated with vascular disease, making them
appealing traits to investigate froma statistical, clinical, and practical
standpoint [3]. The genetic factors underlying variability in blood
lipid levels have been extensively studied using GWAS, in cohorts of
various design [4–16]. Through the construction of biobanks linked
to electronic medical records (EMRs), the clinical community is now
in a position to assess these associations in practice.
There is particularly strong interest in the characterization of
genetic factors underlying population variability in HDL-C [17].
In human populations, every 1 mg/dl decrease in HDL-C is
associated with a 6% increase in cardiovascular risk [18]. HDL
particles also appear to have direct anti-atherogenic properties in
animal models [19]. Therefore, while these smaller particles may
serve as a source of cholesterol esters for the larger, more
atherogenic LDL particles, the HDL particles themselves actually
appear to attenuate the development of cardiovascular disease
[20]. HDL is under tight genetic control (h
2 up to ,70%) [21], yet
despite HDL’s high heritability, even some of the most well
powered GWAS studies have only explained a very small
proportion of HDL variation using common SNPs [9,12,22].
This net unexplained variation due to genetics, often termed the
‘‘missing heritability’’ problem [23], has challenged GWAS studies
for many complex traits beyond circulating lipid levels [2,24].
A general explanation for this missing heritability is that it
reflects forms of genetic variation that are not captured in the
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variation [2,23], epigenetics, and gene-gene (GxG) and gene-
environment (GxE) interactions [2,23,25,26]. GxG interaction
(epistasis) is thought to be an important component of complex,
multifactorial diseases due to the complexity of biological systems
[27]. Data from animal models provide compelling support for the
role of GxG interaction in the control of complex traits [28,29].
Exploration of GxG in GWAS is often limited by lack of large
sample sizes and statistical methods. One possible solution to the
sample size problem is presented by the growing number of DNA
repositories linked to electronic health records. These resources
can provide cohorts of sufficient size for the characterization of
GxG interaction. In parallel, computational capacity and novel
methodologies have emerged to make the search for epistasis in
GWAS feasible [30,31].
Here we present data from a GWAS analyzing HDL-C using
the Marshfield Clinic Personalized Medicine Research Project
(PMRP) database [32], a node of the NHGRI-funded eMERGE
network (electronic Medical Records and Genomics) [www.gwas.
org]. We first conducted a genome-wide scan for SNPs associated
with median HDL-C level using the secure encrypted compre-
hensive EMRs of 3947 PMRP participants. We also constructed a
modeled HDL phenotype that accounts for environmental effects
such as population trends in age, body mass index (BMI), and
relevant co-morbidities [17]. We next investigated GxG interac-
tion in this same dataset, using an approach that leverages existing
biological knowledge [33–35].We required that any GxG
interactions in this cohort (n=3740 PMRP participants) showed
evidence of replication in the de-identified EMRs of a second
cohort from the eMERGE network (n = 1858 records from the
BioVU project [36]). This resulted in replicated GxG interactions




For the discovery cohort in the Marshfield PMRP, the study was
approved by the Institutional Review Board of the Marshfield
Clinic, and conducted in accordance with the basic principles of
the Declaration of Helsinki. All study subjects in the discovery
cohort provided written informed consent allowing access to their
entire electronic medical record, through their participation in
the Marshfield Clinic Personalized Medicine Research Project
(PMRP). For our replication cohort we used samples chosen from
BioVU, Vanderbilt’s DNA databank. BioVU employs novel
informatics strategies to de-identify Vanderbilt’s comprehensive
EMR and link these data to DNA extracted from blood samples
obtained through routine clinical care and that would otherwise be
discarded. Participants have the option of opting out at the clinical
point of care, and the use of this de-identified research resource
has therefore been determined by Vanderbilt’s Institutional
Review Board to represent non-human subject research. The
federal Office of Human Research Protections concurred, and
informed consent was therefore not required for access to the de-
identified information within the BioVU biobank. We maintain a
substantial oversight structure to promote the ethical maintenance
of the resource, and to supervise all research conducted with its
contents. Oversight bodies include: Vanderbilt University Institu-
tional Review Board, the Vanderbilt University Medical Center
Ethics Committee, the External Ethics Advisory Board, the
Community Advisory Board, and the Vanderbilt University legal
department [37]. The PMRP database and BioVU are both
eMERGE nodes, and are two of the largest practice-based
biobanks in the U.S. with over 20,000 in the PMRP and over
100,000 in BioVU as of December, 2010 [36,38,39].
Phenotyping
To facilitate the construction of accurate prediction models for
cardiometabolic risk, the eMERGE network has begun extracting
clinical lipid data from multiple participating sites. Marshfield
Clinic in Central Wisconsin has one of the oldest internally
developed EMRs in the US, with coded diagnoses dating back to
the early 1960’s and laboratory observations dating back to 1985.
The EMR data collected for clinical care is transferred daily into
the Marshfield Clinic Data Warehouse where it is made available
for research. We modeled lipid variables using this data source for
the participants in the Marshfield PMRP cohort [17].
The PMRP demographics reflect the composition of the Central
Wisconsin community, and the corresponding dataset has a
distribution of fasting lipid levels similar to that reported by
NHANES III [40]. At present, the PMRP Biobank contains data
from over 20,000 adult participants; more than 10,000 individuals
(54%) have impaired fasting glucose; .8,000 (41%) have
hypertriglyceridemia; and .9,000 (48%) have reduced levels of
HDL cholesterol according to criteria published by NCEP ATP-
III [41,42].
The eMERGE network design includes selection of ,3,000
subjects with a predesignated phenotype at each node for genome-
wide genotyping. In PRMP, the primary phenotype was cataract
(n=3,947 subjects). This phenotype resulted in a set enriched for
older adults (age range 52 to 90 years, mean age 72). The set
included 3,740 primarily European-American individuals with at
least two fasting HDL measurements available for use in the
present analysis. Due to the longitudinal nature of these data (2 to
78 lipid data points per individual; mean = 14.4610.1 data
points), we defined two phenotypes to be used in the analyses
below: (1) median HDL and (2) modeled HDL as previously
described [17]. All HDL measurements for every individual were
extracted from the EMR.
For the single-locus analysis of HDL level in the Marshfield
PMRP, a simple median HDL level was computed for every
individual who had at least two or more HDL datapoints in the
record. Analyses using median HDL included adjustments for
smoking, age, age
2, BMI, BMI
2, and gender, as all of these factors
showed highly significant associations with median HDL. A
second HDL measurement, termed here as modeled HDL, was
also calculated for individuals in the Marshfield dataset. To
calculate a modeled HDL for an individual, we extracted all lipid
data and censored any HDL data acquired after lipid treatment or
the onset of a relevant co-morbidity, and then used population-
based trends in age and BMI to adjust individual estimates [17].
Records were censored at the first date of diagnosis for the
following clinical co-morbidities known to influence circulating
lipid levels: cancer, diabetes mellitus, and thyroid disease. Cancer
(any malignancy except two common skin cancers - basal cell
carcinoma and squamous cell carcinoma of the skin) was censored
based on ICD-9 codes in the EMR. Thyroid disease and diabetes
were assessed from the EMR using an electronic phenotyping
algorithm available at the eMERGE website (www.gwas.org).
Smoking status was acquired via information provided on a
questionnaire provided at study entry, later confirmed by
interview. Records were also censored at the first date of
prescription for medications known to alter circulating lipid levels
(either therapeutically or indirectly), including statins, fibric acid
derivatives, niacin, and exogenous gonadal steroids. Our selection
of these covariates has been published [17]. The data were
extracted from the EMR using natural language processing (NLP)
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[43], and the programming pseudocode is freely available through
the eMERGE network (www.gwas.org).
For the gene-gene interaction analysis, we replicated findings
using independent samples from BioVU, the EMR-derived DNA
databank at Vanderbilt University Medical Center [36,47]. The
primary eMERGE phenotype at this site is variability in the
duration of the QRS complex on the normal electrocardiogram.
Replication of the gene-gene interaction analysis in the Marshfield
PMRP was conducted in 1,858 European-American and African-
American individuals from the Vanderbilt BioVU dataset having
at least two HDL measurements extracted from a de-identified
synthetic derivative of the EMR. Because the additional clinical
data mentioned above were not available for samples in this
dataset, no modeled HDL could be computed on these data, and
no adjustments were made in the gene-gene interaction analysis. It
is, however, unlikely that any of these variables will confound any
association to a gene-gene interaction replicating across both the
Marshfield PMRP and Vanderbilt BioVU samples.
Genotyping and Quality Control
Genotyping for the Marshfield PMRP samples was performed
as part of the eMERGE network at the Center for Inherited
Disease Research (CIDR) at Johns Hopkins University. The
Illumina Human660W-Quadv1_A genotyping platform was used
for this study. This platform consists of 560,635 SNPs and 96,731
intensity-only probes. Genotyping calls were made at CIDR using
BeadStudio version 3.3.7. Our discovery cohort includes 3,947
samples from the Marshfield PMRP, 21 blind duplicates, and 85
HapMap controls. The HapMap controls include 44 CEPH, 32
Yoruba, 5 Japanese, and 4 Han Chinese; 40 independent
HapMap replicate pair experiments, 19 independent HapMap
trio experiments and 8 independent parent-child pairs were
defined. The HapMap concordance rate was 99.8%. The blind
duplicates reproducibility rate was 99.99%.
Genotyping for the Vanderbilt BioVU samples was performed
as part of eMERGE primarily at the Broad Institute. A small
number of BioVU samples, where the primary phenotype of
interest was dementia were genotyped at CIDR. Similar to the
PMRP samples, most samples were genotyped for SNPs on the
Illumina Human660W-Quadv1_A platform, although a subset of
these samples were genotyped on the Illumina 1M-Duo BeadChip
(those who were known to be African American), which included
all the SNPs on the 660W platform in addition to extra SNPs that
were not considered in this analysis.
Genome-wide SNP data were cleaned using the eMERGE
quality control (QC) pipeline developed by the eMERGE
Genomics Working Group [48]. This process includes evaluation
of sample and marker call rate, gender anomalies, duplicate and
HapMap concordance, batch effects, Hardy-Weinberg equilibri-
um, Mendelian errors, sample relatedness, and population
stratification. We also removed any SNPs with a minor allele
frequency less than 1%, as power to detect associations with these
variants was low. After QC and minor allele frequency filtering,
522,204 SNPs were used for the single locus analysis in the
Marshfield PMRP dataset. Seven individuals were removed due to
low (,99%) call rate. In the Marshfield PMRP cohort, over 98%
of the participants self-reported European-American ancectry.
Reconciling ancestry using self-report, principle components [49],
and structured analysis resulted in exclsuion of a further 37 non-
European genetic ancestry outliers. After excluding these samples,
none of the top ten principal components were significant [49] or
explained more than one tenth of one percent of HDL variation,
and so no adjustment for principal components of ancestry was
used in this sample. For the gene-gene interaction replication set
using Vanderbilt BioVU samples in a combination of both
European-Americans and African-Americans, we identified and
excluded 5 ethnic outliers and adjusted analyses for two marginally
significant principle components using Eigensoft [49]. All
genotype data and detailed documentation of the quality control
procedures summarized here have been deposited and are
available at dbGaP [50].
Statistical analysis
More than half of the individuals in the Marshfield dataset had
a first, second, or third degree relative also in the dataset. To allow
for the inclusion of related individuals without inflating the type I
error rate in the single-locus analysis, we performed the GWAS
analysis using a linear mixed effects analysis [51] with GenABEL
[52] implemented in the R statistical computing environment [53].
Residuals from this model are essentially free from familial
correlations, and can be used in a simple linear regression model
for each SNP, which was performed using PLINK [54]. Genome-
wide statistical significance was determined using a Bonferroni
correction.
One frequently-cited causal mechanism underlying GxG
interaction has been variability within multiple genes in similar
pathways, protein families, or genes with similar or redundant
biological function [33,34]. For analyses of gene-gene interaction,
the Biofilter is a bioinformatics algorithm that leverages domain
knowledge from publicly available biological databases among
SNPs from biologically plausible gene sets sharing physiological or
biochemical similarity (or that have been previously associated
with the phenotype under investigation) [35]. The rationale for
using the Biofilter is to reduce both the computational and
multiple testing burdens inherent in testing for gene-gene
interactions. The Biofilter quantifies evidence in support of a
particular gene-gene interaction model by counting the number of
public database sources that independently link the two genes
within a similar biological mechanism. Choosing to be conserva-
tive, we required that any gene-gene model be independently
supported by four sources of biological knowledge among the
following six: the Gene Ontology[55]; the Database of Interacting
Proteins[56]; the Protein Families Database[57,58]; the Kyoto
Encyclopedia of Genes and Genomes (KEGG)[59]; Reac-
tome[60]; or NetPath[61]. This criterion identified 22,769 SNP-
SNP interactions that were tested for association to HDL-C levels
in the Marshfield PMRP, and significant results were followed up
using the Vanderbilt BioVU cohort. Figure 1 is a flow diagram
illustrating an overview of the analysis plan.
Results
Sample Summary Statistics
Genome-wide association analyses were conducted in the
Marshfield PMRP cohort using 522,204 SNPs which passed
rigorous quality control procedures established by the eMERGE
network. This analysis was performed for both median adjusted
HDL-C and the modeled HDL-C phenotype (censored according
to medication exposure and relevant co-morbidities). Table 1
summarizes the clinical characteristics of the Marshfield popula-
tion. There were 1,541 male and 2,199 female study subjects (total
3,740) with clinical laboratory records containing at least two
fasting HDL measurements that could be used in the median
HDL-C analysis. Of these 3,740 samples, 2,190 had used statins,
883 have had hypothyroidism or hyperthyroidism, 733 have had
cancer, 1,515 reported having ever smoked, and 301 are current
smokers.
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1,142 male and 1,386 female study subjects (total 2,528) with a
clinical laboratory record complete enough to construct a more
rigorous modeled HDL-C phenotype (censored according to
medication exposure and relevant co-morbidities). Although the
sample size for modeled HDL-C was lower than the sample size
for median adjusted HDL-C (because censoring left no analyzable
data for some individuals), we performed the analyses using both
phenotypes. Our reasoning was that modeled HDL-C has the
potential of revealing novel associations otherwise masked by
the presence of anabolic/catabolic disorders and/or clinical
intervention.
Gender was the most reliable clinical predictor of median HDL-
C level in the Marshfield PMRP cohort. The average HDL-C
concentration (6 standard deviation) was 45.9610.9 mg/dl in
males, and 58.5614.3 mg/dl in females, p=2e-163. This
observation is consistent with the established literature [20,42].
We therefore also included gender as a covariate in the model for
each SNP association. The distribution of median HDL-C is
shown in Figure S1. While slightly right-skewed, the distribution
was approximately normal. We therefore fit a linear regression
model for each SNP assuming an additive allelic model on
untransformed HDL-C, as has been done previously [62]. To
allow for related samples without inflating the type I error rate,
regression on each SNP was performed using residuals from the
linear mixed effects model that allowed for a random polygenic
effect (see methods section).
Single Locus GWAS Analysis: Median Adjusted HDL-C
Figure 2 summarizes the results from our genome-wide
association study, showing the –log10(P-value) for each SNP from
the analysis of median HDL-C level, adjusted for smoking, age,
age
2, BMI, BMI
2, and gender. Figure S2 shows the quantile-
quantile plot of the –log10(P-values) from this analysis plotted
against the expected distribution of P-values under the null
hypothesis. Median adjusted HDL-C level in the Marshfield
PMRP cohort was very strongly associated with SNPs in
cholesterol ester transfer protein (CETP) on chromosome 16,
and strongly associated with hepatic lipase (LIPC) on chromosome
15. Both CETP and LIPC have previously been implicated in
Figure 1. Flow diagram overview of the analysis plan. For the single locus analysis in the Marshfield PMRP cohort, a genome-wide association
study was performed for both median and modeled HDL-C (see Phenotyping section in Methods). For the multilocus analysis, the Biofilter was used
to generate putative multilocus interaction models that were tested for association with median HDL-C in the Marshfield PMRP cohort. The
Vanderbilt BioVU cohort was used for replication. See the Methods and Results sections.
doi:10.1371/journal.pone.0019586.g001
Table 1. Descriptive statistics of quantitative clinical variables
in the Marshfield PMRP cohort.
N Median Mean SD Min Max
Age (years) 3,964 72 72.16 11.03 52 90
Weight
(kilograms)
3,925 80.7 82.92 18.63 34.5 186
Height
(centimeters)
3,927 165.1 166.88 9.63 121.9 195.6
BMI (kg/m
2) 3,923 28.8 29.68 5.79 16.1 64.5
Modeled HDL-C
(mg/dl)
2,528 49.1 50.8 13.44 19.8 114.7
Median HDL-C
(mg/dl)
3,740 51 53.4 14.43 22 127.5
doi:10.1371/journal.pone.0019586.t001
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[4,9,10,12,16]. The SNP with the strongest evidence for
association with median HDL-C was rs3764261 (p=1.22e-25),
2.5kb upstream of the CETP transcription start site. This SNP
alone accounted for approximately 3% of the variance in median
adjusted HDL-C level. This SNP is in LD (r
2.0.8 in HapMap
CEU) with rs247616 (not genotyped here), an eQTL which has
been demonstrated to contribute to cis-regulation of CETP mRNA
levels in HapMap lymphoblastoid cell lines [63]. There were
several other strongly associated variants upstream of the CETP
transcription start site, and we observed association between
HDL-C and a well-characterized nonsynonymous coding SNP,
rs5882 (p=4.1e-7), known to encode a valine to isoleucine change
at amino acid position 422 in the CETP gene product. A previous
study in Ashkenazi Jews with exceptional longevity has revealed
that individuals with the V/V genotype at this site demonstrate
increased lipoprotein sizes and lower serum CETP concentration,
both of which are heritable and promote successful aging [64].
The other signal observed at a level of genome-wide significance
was in hepatic lipase (LIPC). Variants in this gene have also been
associated with HDL-C level in several previous studies
[4,9,10,12,16]. The SNP in the LIPC locus with the strongest
association in our study cohort was rs11855284 (p=3.92e-14),
residing 13.5kb upstream of the LIPC transcription start site on
chromosome 15. The most significantly associated SNP within the
LIPC genic region was intronic SNP rs261336 (p=5.25e-6). These
two SNPs explained 1.6% and 0.5% of the variance in HDL-C
cholesterol, respectively.
Our most significant signal that did not meet genome-wide
significance was rs12678919 (p=1.99e-7), a SNP in an intergenic
region 19kb downstream of lipoprotein lipase (LPL) on chromo-
some 8. This SNP explained 0.7% of the variance in HDL
cholesterol. It is noteworthy that a different variant at the LPL
locus (rs253) was identified in subsequent gene-gene interaction
analyses here. Details are discussed further below.
Single Locus GWAS Analysis: Modeled HDL-C
Our data were derived from an electronic medical record.
Therefore, we also tested each SNP for genome-wide association
with modeled HDL-C as the outcome, a trait which censors by
onset of relevant co-morbidities or usage of lipid-modifying drugs
and adjusts for population trends in age and BMI [17]. Because
this more rigorous phenotype required data for several covariates,
complete data was only available on 2,528 samples in the
Marshfield PMRP cohort. Using 1,156 fewer samples we still
reproduced the genome-wide significant association to CETP
Figure 2. Summary of genome-wide association results. This plot shows the –log10(P-values) from linear mixed effects regression model using
the natural log tranformed median HDL-C level in the Marshfield PMRP sample, adjusted for smoking, age, age
2, BMI, BMI
2, and gender. The red line
indicates a Bonferroni-corrected significance threshold. Genes described in the results and the discussion sections are highlighted in green: ADIPOQ
(chromosome 3), LPL (chromosome 8), TRIB1 (chromosome 8), APOA1/C3/A4/A5 (chromosome 11), LIPC (chromosome 15), and CETP (chromosome 16).
doi:10.1371/journal.pone.0019586.g002
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both LPL (rs1441762, p=1.53e-6) and LIPC (rs11856159,
p=1.59e-6). Full results are available via Table S1 for SNPs
associated at p,1610
-5 with either median or modeled HDL-C.
Interestingly, even though using modeled HDL-C as the
phenotype resulted in a decreased sample size, the association
signal was stronger for certain regions of the genome than when
using median adjusted HDL-C. Despite using lower numbers, we
observed improvement in the strength of association by more than
two orders of magnitude, for many variants included in this
genome-wide SNP scan, when the HDL-C trait was modeled (e.g.,
CENTG2, COL23A1, CACNA2D1, CYB5B, FHOD3, GBX2, TRIB1,
TLE4, TMEM135, UBE3A). As shown in Figure 3, this effect was
most pronounced for SNPs in or near TRIB1, the Tribbles
homolog 1 gene (rs2385114, an intronic SNP, p=8.96e-5;
rs4871603, 30kb downstream, p=2.61e-6). Our ability to resolve
this association strengthened when these variables were consid-
ered. TRIB1 was also associated at the genome-wide level with
triglyceride concentration in our data (most significant SNP,
rs6982502, p=3.7e-9, data not shown). Because we observed a
very strong logarithmic correlation between median triglyceride
level and median HDL-C cholesterol level (Figure S3), we further
assessed the TRIB1-HDL-C relationship using multiple linear
regression, adjusting for triglyceride concentration in addition to
the other clinical variables (e.g., age, gender, BMI and smoking
status). In the analysis adjusting for triglyceride level the effect of
TRIB1 was highly attenuated (p=0.0056). These results empha-
size the need for evaulating data with and without strategies that
censor the longitudinal strings of lipid data based on medication
(e.g., niacin) and relevant co-morbidity (e.g., diabetes).
Gene-Gene Interaction Analysis and Replication
We have demonstrated that biobanks linked to EMR data can
provide a unique resource for robust replication of previous
GWAS findings, and they have the capability of uncovering novel
genetic associations. However, as in other studies, even our most
significant findings individually explain only a small proportion of
the variance in HDL-C level. We next leverage both the PMRP
cohort and a similarly phenotyped cohort from the Vanderbilt
BioVU EMR-linked biobank to investigate gene-gene interactions
and HDL-C. Table 2 summarizes the clinical characteristics of the
Vanderbilt BioVU population.
The number of possible SNP-SNP interactions among 522,204
SNPs is over 1.36610
11. In addition to being extremely
computationally intensive, exhaustive evaluation of all possible
pairwise (SNP-SNP) interactions among GWAS data comes with
an extraordinary loss of power due to the extremely large number
of statistical tests being performed. This mandates prioritization of
which interactions to test based on some intrinsic aspect of the
data or other extrinsic domain knowledge. One data-driven
approach is to select SNPs based on the strength and statistical
significance of their independent main effects, evaluating interac-
tions only between SNPs that meet a certain effect size or
significance threshold [65]. This strategy makes the simplifying but
unnecessary assumption that gene-gene interactions affecting the
phenotype can only occur between SNPs that independently have
a detectable effect on the trait. Instead, we used the Biofilter
(described in the methods section) to prioritize a small subset of
SNP-SNP interactions to test for association with HDL-C level
using existing extrinsic biological knowledge. It is of note that this
method does not require that any SNP have an independent
statistically significant main effect.
We performed a gene-gene interaction analysis using multiple
linear regression allowing for a multiplicative interaction term
between the two additive-encoded SNPs. Requiring that SNP-
SNP models be supported by at least four sources of extrinsic
domain knowledge (see Statistical Analysis in Methods section), we
tested 22,769 SNP-SNP interactions in the Marshfield PMRP
cohort. Two test statistics were generated for each model tested: a
t-test on the multiplicative interaction term (Pixn), and an F-test on
the overall model (Pmod). A significant Pixn indicates a significant
non-zero multiplicative gene-gene interaction between the two
SNPs while a significant Pmod indicates a significant overall model
(i.e. R
2.0). We required both statistics to be significant in both
datasets, further constraining our results to well-fitting models with
strong evidence of non-additive gene-gene interaction.
Figure 3. Association results for the TRIB1 region. This shows the association results for the Tribbles 1 Homolog (TRIB1) region, for median
adjusted HDL-C (left) and modeled HDL-C (right) in the Marshfield PMRP cohort. Color scale displays the degree of linkage disequilibrium (r
2) between
markers. Blue line shows recombination rate from HapMap CEU. Gene location is shown along the horizontal axis of each panel. This plot shows that
while the statistical significance of the effect of TRIB1 on HDL-C levels is less compelling when adjusting for triglyceride concentration, the association
is much stronger when using the modeled HDL-C phenotype (even though this phenotype has far fewer samples than the median adjusted HDL-C
phenotype). SNP rs4871603 in TRIB1 was associated with median HDL-C at p=7.06e-4 and with modeled HDL-C at p=2.61e-6 without adjusting for
triglyceride concentration. After adjusting for triglycerides, the p-values for median and modeled HDL-C become less significant (p=0.296 and
p=0.0056, respectively, data not displayed).
doi:10.1371/journal.pone.0019586.g003
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cant interaction term and ANOVA p-values (Pixn,0.01 and
Pmod,0.05), indicative of non-additive gene-gene interaction in a
well-fitting model contributing to median HDL-C level. Because of
the linkage disequilibrium existing between SNPs in the same
gene, and because tests of SNP-SNP interaction often include the
same SNP being tested for interaction with other SNPs, the test
statistics from this procedure can be highly correlated. Further-
more, an appropriate permutation test would require permutation
of not only the phenotype but permutation of the SNP-SNP
linkages in our sources of biological knowledge, and methodology
to appropriately carry out such a permutation procedure has yet to
be developed or tested. Because it is unclear how to properly
correct for multiple testing in these datasets, we opted to require
replication in a second cohort. These 11 SNP-SNP interaction
models were therefore tested in the BioVU cohort, adjusting for
two significant principal components to avoid any potential
confounding by population stratification. Of the 11 models that
were significant in the initial screen, six replicated in the BioVU
replication cohort. Statistical significance thresholds for the
replication cohort were slightly more liberal (Pixn,0.05,
Pmod,0.1) to avoid excessive type II errors due to the smaller
sample size.
The results highlighting these 11 significant gene-gene interac-
tion models are summarized in Table 3 (models indicated by one
or more stars). The six models that show evidence for replication
in the BioVU cohort are indicated by two or more stars. These six
models are representative of four distinct gene-gene interactions:
GALNT1-GALNT2, GALNT2-GALNT3 (members of the GalNAc-
transferases family), LPL-ABCA1 (lipoprotein lipase and ATP
Binding Casette A1), and RPA2-RPA3 (Replication Protein A 2/3).
We then refined our results highlighting models that were
significant in the Marshfield cohort, replicate in the BioVU cohort,
and where all coefficients were in the same direction – that is, if the
coeffieicnt for either SNP or the interaction term is positive in the
Marshfield cohort, the corresponding coefficient must also be
positive in the BioVU dataset. This stringent criterion further
reduced our replicating models to two similar interaction models
involving LPL and ABCA1 (models indicated by three stars in
Table 3): rs2536rs2515614 and rs2536rs2472509. These two
models were statistically redundant - the ABCA1 SNPs (rs2515614
and rs2472509) were in extremely high linkage disequilibrium
(r
2=1 in Marshfield, r
2=0.99 in BioVU), resulting in nearly
identical coefficients and test statistics. One characteristic of this
LPL-ABCA1 interaction warrants special emphasis. In this model
the direction of the main effects (b1 and b2) were all in the same
direction, while the interaction effects were in the opposite
direction. That is, in both datasets, inheriting a minor allele at
either locus (but not both) results in a dosage-dependent decrease
in HDL-C level, while inheriting a minor allele at both variants
results in a change that is significantly higher than the expected
change caused by the additive effects of both variants alone. It may
be that, while either SNP alone can impact the production and/or
vascular remodeling of HDL particles, the two variants together
alter the TG/HDL ratio and particle stability.
Discussion
We performed a genome-wide association analysis of HDL
cholesterol level in two large clinical practice-based biobanks. We
observed a number of previously reported associations between
HDL-C level and genes impacting lipoprotein homeostasis (e.g.,
CETP, LIPC, LPL). Furthermore, our approach using an electronic
phenotyping algorithm to censor based on clinical factors known
to influence HDL-C cholesterol levels allowed us to identify genes
that are more strongly associated in the context of clinical
covariates (e.g.,TRIB1). Finally, we investigated gene-gene inter-
action using a novel bioinformatics approach that restricts the
number of pairwise tests based on existing biological knowledge.
The primary phenotype utilized in this study was median HDL
cholesterol level, derived from longitudinal clinical data. This trait
was determined from laboratory data obtained during routine
clinical care, and available within each subject’s individual
electronic medical record. In the single-locus analysis, the SNP
most strongly associated with median HDL-C level was rs3764261
(p=1.22e-25), 2.5 kb upstream of the CETP transcription start site
on chromosome 16. This SNP alone accounted for approximately
3% of the variance in median adjusted HDL-C level. This same
variant had also been reported in another genome-wide
association study in the Northern Finland Birth Cohort
(p=6.97e-29) [12], and a meta analysis of three genome-wide
association studies initially comprising 8,656 individuals and
,2,261,000 imputed and/or genotyped SNPs (p=2.8e-19) [16],
followed by validation in six European cohorts totaling 11,569
individuals (p=6.4e-43) [16]. Other studies have found different
SNPs in the region upstream of CETP to be even more highly
associated with HDL cholesterol levels: rs1800775 (p=1e-73) in
[9], rs173539 (p=4e-75) in [10] where samples were combined
from the two previously cited studies, and rs1532624 (p=9.4e-94)
in [4]. The SNP with the strongest association in our dataset
(rs3764261) is in LD with an eQTL SNP which affects mRNA
levels of CETP in HapMap lymphoblastoid cell lines [63]. The
CETP gene product has known biological relevance, redistributing
cholesterol esters and triglycerides between HDL-C particles and
the larger, more atherogenic lipoproteins.
Free fatty acids and triglycerides are liberated from HDL-C
particles through the activity of three well-characterized lipolytic
enzymes (LIPC, LIPG, and LPL). In our dataset, a SNP in the first
gene reaching genome-wide significance for association with
HDL-C level was rs11855284 (p=3.90e-14), 13.5kb upstream of
the hepatic lipase (LIPC) transcription start site on chromosome
15. Further, our most significant signal that did not meet genome-
wide significance was rs12678919 (p=1.99e-7), a SNP in an
intergenic region 19kb downstream of lipoprotein lipase (LPL)o n
chromosome 8. Thus, we observed association with LPL and LIPC
but not LIPG. These observations are consistent with existing
biological knowledge. The enzymatic activity of LPL favors
lipolysis of triglyceride (i.e., phospholipase activity is relatively
minor). Triglyceride rich HDL-C particles are less stable, and are
quickly shuttled back to the liver for elimination, as SRB1
mediated removal is a function of triglyceride enrichment in HDL-
Table 2. Descriptive statistics of quantitative clinical variables
in the Vanderbilt BioVU cohort.
N Median Mean SD Min Max
Age (years) 2,576 57 56.56 15.85 19 90
Weight
(kilograms)
2,522 85.16 88.05 24.62 36.29 251.74
Height
(centimeters)
2,294 167.64 168.5 10.01 129.54 203.2
BMI (kg/m
2) 2,292 29.44 30.98 7.94 14.63 72.5
Median HDL-C
(mg/dl)
2,576 50.0 53.20 17.320 9.0 146.0
doi:10.1371/journal.pone.0019586.t002
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activity, (i.e., primarily a phospholipase), and any common
variants that affect expression or function of LIPG would have
small effect on HDL-C stability, requiring a very large sample size
to detect an association (,9,800 samples to achieve 80% power to
detect an effect of similar magnitude as has been previously
observed for LIPG [16] at p=1e-7).
When we used our previously developed approach to modeling
HDL-C within an electronic record, which censors data based on
relevant co-morbidities (e.g., diabetes mellitus) and lipid modifying
medications (e.g., niacin), we identified several loci that were more
strongly associated, with HDL-C, even though we had a reduced
sample size. SNPs in and near TRIB1 were more strongly
associated with modeled HDL-C level using a lower sample size
(n=2528, p=2.61e-6), versus using a simple median HDL-C
(n=3903, p=7.06e-4). TRIB1 resisted identification in all
previous GWAS studies of HDL-C, and was only recently
reported for the first time in a meta-analysis of over 100,000
samples[62]. In our data, HDL-C and triglyceride levels were
logarithmically correlated (Figure S3), and the association between
rs4871603 in TRIB1 and modeled HDL-C (p=2.61e-6) was
markedly reduced after adjusting for triglyceride level (p=0.0056).
Further study is warranted to fully characterize the biology
underlying this interaction. TRIB1 may serve as a clinical
surrogate for the triglyceride effect on HDL-C concentration.
TRIB1 encodes a G-protein-coupled-receptor induced protein
involved in the function of mitogen-activated protein kinases [66],
and the role of HDL-C in reverse cholesterol transport may be
modulated through such an interaction [67269]. Because TRIB1
has previously been associated with coronary artery disease
[4,9,10,16], the TRIB1-HDL-C relationship observed within our
data may have a profound impact on public health.
Our most significant findings, however, still explain less than
5% of the variance in HDL-C level, a trait that is up to 70%
heritable. We therefore examined a small subset of all the possible
gene-gene interactions in our GWAS data. We found 11
interactions that were nominally significant in our discovery
cohort (the Marshfield PMRP biobank). After evaluating these
models in a validation sample (Vanderbilt BioVU cohort), we
found that six of the 11 models replicated. We required both the p-
value on the interaction term and the p-value on the ANOVA F-
test for the regression model to be significant in both datasets,
further constraining our results to models with evidence of
nonlinear gene-gene interaction in a well-fitting model. These
models individually explained 0.220.8% of the variation in HDL-
C in the Marshfield and BioVU cohorts (see Table 3). Only one set
of observed gene-gene interactions showed evidence of replication
in both datasets with consistent directionality in all three
coefficients: LPL and ABCA1. Because we required evidence of
replication with consistent direction of effect in a second dataset,
we did not require a stringent multiple testing correction. While it
would be possible to randomize the outcome data and permute
this entire procedure, this method of permutation testing would be
computationally intensive, and such a method has not yet been
standardized for the permutation of the SNP-SNP linkages
available in our sources of biological knowledge. Furthermore,
this permutation test on an interaction term would have a more
restrictive null hypothesis (no association) than the null hypothesis
we wish to test (no interaction). Biologically, LPL mediates the
release of free fatty acids and triglyceride from HDL-C particles,
while ABCA1 moves free cholesterol into HDL-C particles as they
undergo intravascular remodeling. Thus, it is not surprising that
we observed a statistically meaningful interaction between variants
in these two genes. It is however surprising that the direction of the
main effect coefficients (b1 and b2) were in the same direction
while the interaction effect was in the opposite direction. While still
considered a nonlinear epistatic interaction, the structure of the
model in Table 3 is referred to as a heterogeneity model [70,71] rather
than a synergistic multiplicative model. In a separate study of type
I diabetes, investigators found that four out of five statistically
significant gene-gene interactions were also of this type [72].
Genetic heterogeneity is a serious concern with large-scale genetic
studies, and is often cited as a reason for the widespread lack of
replication in GWAS studies [73,74]. Others have recently argued
that epistatic genetic heterogeneity should be considered when
analyzing genetic data for association to complex human traits
[75]. Despite the fact that statistical tools, such as random forests,
have been available for some time now to accomplish this [76,77],
Table 3. Gene-gene interaction models.
REP SNP 1 Gene 1 SNP 2 Gene 2 M b1 M b2 M b3 MP ixn MP mod MR
2 V b1 V b2 V b3 VP ixn VP mod VR
2
* rs3927911 BCL2 rs4645900 BAX 0.213 3.901 23.890 0.004 0.018 0.003 0.805 5.397 25.808 0.042 0.154 0.003
* rs2271709 C7 rs6699859 C8A 1.203 1.068 21.776 0.005 0.028 0.002 21.173 21.176 2.433 0.020 0.138 0.003
* rs910497 GALNT2 rs4621175 GALNT3 20.727 21.250 2.347 0.003 0.013 0.003 20.890 21.976 2.148 0.024 0.129 0.003
* rs4621175 GALNT3 rs4846930 GALNT2 21.213 20.726 2.291 0.004 0.014 0.003 21.750 20.955 2.261 0.017 0.100 0.003
* rs4621175 GALNT3 rs10864732 GALNT2 21.179 20.726 2.243 0.004 0.017 0.003 21.641 20.985 2.245 0.019 0.106 0.003
** rs886724 RPA3 rs7536088 RPA2 1.493 1.713 21.818 0.000 0.002 0.004 22.064 21.266 1.995 0.019 0.099 0.003
** rs886724 RPA3 rs17257252 RPA2 0.890 1.182 21.703 0.003 0.029 0.002 22.035 21.938 2.795 0.007 0.046 0.004
** rs901675 GALNT2 rs4621175 GALNT3 1.216 2.109 22.521 0.004 0.004 0.004 22.114 21.512 2.535 0.037 0.077 0.004
** rs1471915 GALNT2 rs12963790 GALNT1 20.410 20.447 2.778 0.004 0.020 0.003 22.114 0.098 23.487 0.037 0.002 0.008
*** rs253 LPL rs2515614 ABCA1 20.340 21.098 1.441 0.006 0.011 0.003 20.618 22.797 2.790 0.001 0.006 0.007
*** rs253 LPL rs2472509 ABCA1 20.338 -1.113 1.438 0.006 0.011 0.003 20.399 22.797 2.790 0.001 0.006 0.007
This table shows 11 significant gene-gene interaction models discovered in the Marshfield PMRP cohort (M Pixn,0.01 and M Pmod,0.05, indicated by one to three stars).
Six of these models show evidence for replication in the Vanderbilt BioVU cohort (M Pixn,0.05, M Pmod,0.1, indicated by two to three stars). In two of these replicating
models, all three pairs of coefficients were in the same direction in both datasets (indicated by three stars). The table shows the two SNPs and their corresponding genes
involved in the gene-gene interaction. All SNPs here were intronic SNPs. The coefficients for the main effects (b1 and b2) and the interaction term (b3) are shown for both
the Marshfield cohort (prefixed by ‘‘M’’), and the Vanderbilt cohort (prefixed by ‘‘V’’). Also shown are the interaction term p-values (Pixn), ANOVA model fit p-values
(Pmod), and overall R
2 statistics for both the Marshfield and Vanderbilt cohorts (prefixed by ‘‘M’’ and ‘‘V’’ respectively).
doi:10.1371/journal.pone.0019586.t003
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heterogeneity is a task rarely undertaken. Accounting for genetic
heterogeneity in genetic studies of complex disease may improve
the replicability of findings in genome-wide studies of lipid and
other phenotypes.
In summary, we have used EMR data from genotyped
biobanked samples to perform the first knowledge-driven gene-
gene interaction analysis for HDL-C. Using a second EMR-linked
biobank cohort we demonstrated evidence for replication of a
gene-gene interaction between LPL and ABCA1. As demonstrated
here and elsewhere [36,78], biobank-linked EMRs provide an
excellent resource for genetic studies of complex traits. By utilizing
the EMR to construct a rigorous phenotype and by accounting for
gene-gene interaction as presented here, perhaps more variation
can be explained and new biology discovered in complex traits like
HDL-C level.
Supporting Information
Figure S1 Distribution of HDL-C concentration (mg/dL) in
males (blue) and females (red) in the Marshfield PMRP dataset.
(TIF)
Figure S2 Quantile-quantile plot of the –log10(P-values) from
the median adjusted HDL-C analysis in the Marshfield PMRP
cohort plotted against the expected null distribution.
(TIF)
Figure S3 Median HDL-C and median triglyceride concentra-
tions are highly logarithmically correlated (r
2=.258). Trend line 6
95% confidence interval is shown.
(TIF)
Table S1 All single locus SNPs associated at p,1610-5 with
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